The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity.
This paper reports the results of the first field study performed to assess the safety, immunogenicity and protectivity of the synthetic malaria vaccine SPf66 directed against the asexual blood stages of Plasmodium falciparum. Clinical and laboratory tests were performed on all volunteers prior to and after each immunization, demonstrating that no detectable alteration was induced by the immunization process. The vaccines were grouped as high, intermediate or low responders according to their antibody titres directed against the SPf66 molecule. Two of the 185 (1.08%) SPf66-vaccinated and nine of the 214 (4.20%) placebo-vaccinated volunteers developed P. falciparum malaria. The efficacy of the vaccine was calculated as 82.3% against P. falciparum and 60.6% against Plasmodium vivax.
Amador
R
R
Instituto de Inmunología, Hospital San Juan de Dios, Bogotá, Colombia.
Moreno
A
A
Valero
V
V
Murillo
L
L
Mora
A L
AL
Rojas
M
M
Rocha
C
C
Salcedo
M
M
Guzman
F
F
Espejo
F
F
D000595:Amino Acid Sequence; D000818:Animals; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D016778:Malaria, Falciparum / Q000517:prevention & control*; D008297:Male; D008969:Molecular Sequence Data; D010963:Plasmodium falciparum / Q000276:immunology*; D011446:Prospective Studies; D016052:Protozoan Vaccines / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use
D016052:Protozoan Vaccines; D014614:Vaccines, Synthetic